VISCHER advised private investors who acquired shares in Molecular Partners AG (SIX: MOLN) from venture capitalist funds in secondary block trades. Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new class of drugs, known as DARPin® therapies.

The team at VISCHER was lead by Dr. Matthias Staehelin (Partner) with Sebastian Flückiger (Associate) both Corporate.